Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double–blind, placebo–controlled trial

US Tizanidine Study Group

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Article abstract This multicenter, stratified, randomized, placebo-controlled, double-blind trial evaluated tizanidine for use in the United States for spasticity secondary to MS. The 15-week trial was divided into baseline (weeks 0 and 11, titration (2 mg to a maximum of 36 mg/d; weeks 2 to 41, and plateau (weeks 5 to 13) phases, followed by dose tapering (week 14) and a final visit (week 15). Primary efficacy parameters were scores on muscle tone (Ashworth Scale) and type and frequency of muscle spasms (patient diaries). All efficacy parameters were evaluated by the physiciadassessor, and the physiciadprescriber was responsible for all dosage adjustments. The patient, physiciadassessor, and physiciadprescriber made global evaluations of antispastic efficacy. Tizanidine produced a significantly greater reduction than placebo in spasms and clonus (patient diaries) but no significant differences in Ashworth scores. Patients and physiciadprescribers, but not physicadassessors, gave significantly better scores in the overall assessment of efficacy and tolerability. No significant differences in other secondary efficacy parameters were noted. Adverse events were reported for 66 (61%) of the 109 placebo-treated patients and 101 (91%) of the 111 tizanidine-treated patients; 6 (6%) and 14 (13%) discontinued treatment, respectively. Patient and physician perception of improvement demonstrated more consistent differences between groups than did the Ashworth Scale, perhaps because of inexperience with this measure or failure to consider time between drug administration and assessment.

Original languageEnglish (US)
Pages (from-to)S34-S42
JournalNeurology
Volume44
Issue number11
StatePublished - 1994
Externally publishedYes

Fingerprint

Multiple Sclerosis
Placebos
Spasm
Therapeutics
Social Adjustment
tizanidine
Efficacy
Physicians
Muscles
Pharmaceutical Preparations
Placebo

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Tizanidine treatment of spasticity caused by multiple sclerosis : Results of a double–blind, placebo–controlled trial. / US Tizanidine Study Group.

In: Neurology, Vol. 44, No. 11, 1994, p. S34-S42.

Research output: Contribution to journalArticle

@article{dbe6d6d197a1461285e128643c3cb888,
title = "Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double–blind, placebo–controlled trial",
abstract = "Article abstract This multicenter, stratified, randomized, placebo-controlled, double-blind trial evaluated tizanidine for use in the United States for spasticity secondary to MS. The 15-week trial was divided into baseline (weeks 0 and 11, titration (2 mg to a maximum of 36 mg/d; weeks 2 to 41, and plateau (weeks 5 to 13) phases, followed by dose tapering (week 14) and a final visit (week 15). Primary efficacy parameters were scores on muscle tone (Ashworth Scale) and type and frequency of muscle spasms (patient diaries). All efficacy parameters were evaluated by the physiciadassessor, and the physiciadprescriber was responsible for all dosage adjustments. The patient, physiciadassessor, and physiciadprescriber made global evaluations of antispastic efficacy. Tizanidine produced a significantly greater reduction than placebo in spasms and clonus (patient diaries) but no significant differences in Ashworth scores. Patients and physiciadprescribers, but not physicadassessors, gave significantly better scores in the overall assessment of efficacy and tolerability. No significant differences in other secondary efficacy parameters were noted. Adverse events were reported for 66 (61{\%}) of the 109 placebo-treated patients and 101 (91{\%}) of the 111 tizanidine-treated patients; 6 (6{\%}) and 14 (13{\%}) discontinued treatment, respectively. Patient and physician perception of improvement demonstrated more consistent differences between groups than did the Ashworth Scale, perhaps because of inexperience with this measure or failure to consider time between drug administration and assessment.",
author = "{US Tizanidine Study Group} and Charles Smith and Gary Birnbaum and Carter, {Jonathan L.} and Jeffery Greenstein and Lublin, {Fred D.} and Bernard Baumel and Hsu, {Chung Y.} and Frances Murphy and Reader, {Anthony T.} and Schapiro, {Randall T.} and Sibley, {William A.} and Antonio Stazio and Trotter, {John L.} and Vollmer, {Timothy L.} and Walshe, {Thomas M.}",
year = "1994",
language = "English (US)",
volume = "44",
pages = "S34--S42",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Tizanidine treatment of spasticity caused by multiple sclerosis

T2 - Results of a double–blind, placebo–controlled trial

AU - US Tizanidine Study Group

AU - Smith, Charles

AU - Birnbaum, Gary

AU - Carter, Jonathan L.

AU - Greenstein, Jeffery

AU - Lublin, Fred D.

AU - Baumel, Bernard

AU - Hsu, Chung Y.

AU - Murphy, Frances

AU - Reader, Anthony T.

AU - Schapiro, Randall T.

AU - Sibley, William A.

AU - Stazio, Antonio

AU - Trotter, John L.

AU - Vollmer, Timothy L.

AU - Walshe, Thomas M.

PY - 1994

Y1 - 1994

N2 - Article abstract This multicenter, stratified, randomized, placebo-controlled, double-blind trial evaluated tizanidine for use in the United States for spasticity secondary to MS. The 15-week trial was divided into baseline (weeks 0 and 11, titration (2 mg to a maximum of 36 mg/d; weeks 2 to 41, and plateau (weeks 5 to 13) phases, followed by dose tapering (week 14) and a final visit (week 15). Primary efficacy parameters were scores on muscle tone (Ashworth Scale) and type and frequency of muscle spasms (patient diaries). All efficacy parameters were evaluated by the physiciadassessor, and the physiciadprescriber was responsible for all dosage adjustments. The patient, physiciadassessor, and physiciadprescriber made global evaluations of antispastic efficacy. Tizanidine produced a significantly greater reduction than placebo in spasms and clonus (patient diaries) but no significant differences in Ashworth scores. Patients and physiciadprescribers, but not physicadassessors, gave significantly better scores in the overall assessment of efficacy and tolerability. No significant differences in other secondary efficacy parameters were noted. Adverse events were reported for 66 (61%) of the 109 placebo-treated patients and 101 (91%) of the 111 tizanidine-treated patients; 6 (6%) and 14 (13%) discontinued treatment, respectively. Patient and physician perception of improvement demonstrated more consistent differences between groups than did the Ashworth Scale, perhaps because of inexperience with this measure or failure to consider time between drug administration and assessment.

AB - Article abstract This multicenter, stratified, randomized, placebo-controlled, double-blind trial evaluated tizanidine for use in the United States for spasticity secondary to MS. The 15-week trial was divided into baseline (weeks 0 and 11, titration (2 mg to a maximum of 36 mg/d; weeks 2 to 41, and plateau (weeks 5 to 13) phases, followed by dose tapering (week 14) and a final visit (week 15). Primary efficacy parameters were scores on muscle tone (Ashworth Scale) and type and frequency of muscle spasms (patient diaries). All efficacy parameters were evaluated by the physiciadassessor, and the physiciadprescriber was responsible for all dosage adjustments. The patient, physiciadassessor, and physiciadprescriber made global evaluations of antispastic efficacy. Tizanidine produced a significantly greater reduction than placebo in spasms and clonus (patient diaries) but no significant differences in Ashworth scores. Patients and physiciadprescribers, but not physicadassessors, gave significantly better scores in the overall assessment of efficacy and tolerability. No significant differences in other secondary efficacy parameters were noted. Adverse events were reported for 66 (61%) of the 109 placebo-treated patients and 101 (91%) of the 111 tizanidine-treated patients; 6 (6%) and 14 (13%) discontinued treatment, respectively. Patient and physician perception of improvement demonstrated more consistent differences between groups than did the Ashworth Scale, perhaps because of inexperience with this measure or failure to consider time between drug administration and assessment.

UR - http://www.scopus.com/inward/record.url?scp=19244369207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244369207&partnerID=8YFLogxK

M3 - Article

C2 - 7970009

AN - SCOPUS:19244369207

VL - 44

SP - S34-S42

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -